全文获取类型
收费全文 | 2293篇 |
免费 | 230篇 |
国内免费 | 29篇 |
专业分类
耳鼻咽喉 | 13篇 |
儿科学 | 195篇 |
妇产科学 | 35篇 |
基础医学 | 298篇 |
口腔科学 | 103篇 |
临床医学 | 238篇 |
内科学 | 420篇 |
皮肤病学 | 75篇 |
神经病学 | 75篇 |
特种医学 | 202篇 |
外科学 | 361篇 |
综合类 | 47篇 |
预防医学 | 156篇 |
眼科学 | 43篇 |
药学 | 89篇 |
中国医学 | 2篇 |
肿瘤学 | 200篇 |
出版年
2023年 | 15篇 |
2022年 | 12篇 |
2021年 | 23篇 |
2020年 | 19篇 |
2019年 | 14篇 |
2018年 | 53篇 |
2017年 | 50篇 |
2016年 | 49篇 |
2015年 | 68篇 |
2014年 | 86篇 |
2013年 | 139篇 |
2012年 | 79篇 |
2011年 | 67篇 |
2010年 | 95篇 |
2009年 | 114篇 |
2008年 | 61篇 |
2007年 | 80篇 |
2006年 | 85篇 |
2005年 | 59篇 |
2004年 | 52篇 |
2003年 | 38篇 |
2002年 | 49篇 |
2001年 | 34篇 |
2000年 | 39篇 |
1999年 | 45篇 |
1998年 | 109篇 |
1997年 | 98篇 |
1996年 | 101篇 |
1995年 | 66篇 |
1994年 | 78篇 |
1993年 | 41篇 |
1992年 | 40篇 |
1991年 | 52篇 |
1990年 | 37篇 |
1989年 | 40篇 |
1988年 | 43篇 |
1987年 | 52篇 |
1986年 | 50篇 |
1985年 | 39篇 |
1984年 | 27篇 |
1983年 | 26篇 |
1982年 | 30篇 |
1981年 | 21篇 |
1980年 | 23篇 |
1979年 | 20篇 |
1977年 | 17篇 |
1976年 | 18篇 |
1975年 | 16篇 |
1973年 | 12篇 |
1967年 | 9篇 |
排序方式: 共有2552条查询结果,搜索用时 0 毫秒
61.
62.
63.
64.
Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies 总被引:6,自引:7,他引:6
Bi L; Sarkar R; Naas T; Lawler AM; Pain J; Shumaker SL; Bedian V; Kazazian HH Jr 《Blood》1996,88(9):3446-3450
65.
Maternal administration of granulocyte colony-stimulating factor improves neonatal rat survival after a lethal group B streptococcal infection 总被引:2,自引:0,他引:2
Novales JS; Salva AM; Modanlou HD; Kaplan DL; del Castillo J; Andersen J; Medlock ES 《Blood》1993,81(4):923-927
Maternally administered recombinant human granulocyte colony- stimulating factor (rhG-CSF) has been shown to cross the placenta and induce a peripheral neutrophilia and increases in the marrow and spleen neutrophil storage pools in fetal and newborn rats. In the present study, we have used this model system to investigate the efficacy of prenatally administered rhG-CSF on neonatal defense to a lethal challenge with Group B-beta hemolytic Streptococcus (GBS). Pregnant rats were injected with rhG-CSF twice daily beginning 6 days before parturition. At birth, all pups were infected with a dose of GBS that is lethal for 90% of infected pups (LD90). Survival was monitored daily for 5 days. Survival of infected pups from saline-treated mothers beyond 60 hours after infection was 10%. No difference in survival was observed among pups from mothers treated 2 and 4 days before parturition. In contrast, we determined that survival was 82.5% among infected pups from mothers treated for 6 days before parturition with rhG-CSF. Our results demonstrate that maternal administration of rhG- CSF augments neonatal defenses against a lethal bacterial challenge. 相似文献
66.
de Koning JP; Dong F; Smith L; Schelen AM; Barge RM; van der Plas DC; Hoefsloot LH; Lowenberg B; Touw IP 《Blood》1996,87(4):1335-1342
67.
Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation. 总被引:3,自引:0,他引:3
Busulfan (BU) is a widely used myeloablative and antineoplastic agent in clinical bone marrow transplantation (BMT). The lower incidence of BU-associated toxicities and lower therapeutic effectiveness in young children given BU doses based on body weight (ie, 16 mg/kg) is associated with altered pharmacokinetics of BU; the area under the curve (AUC) of BU concentration versus time is significantly less in these patients than those observed in older children and adults. To optimize BU dosage in young BMT recipients, we developed a dosage regimen based on body surface area (BSA) and determined BU pharmacokinetics and BU-associated toxicities. Seven children (median age, 3.9 years, range, 1.1 to 5.7) undergoing allogeneic or autologous BMT for leukemia received 40 mg/m2/dose BU every 6 hours for 16 doses; BU concentrations were measured in the plasma, and AUCs were determined for each patient after the first and 13th doses. Expressed as a function of body weight, the median BU dosage was 26.4 mg/kg (range, 24.3 to 28.2), a 60% increase over the BU dosage based on body weight. Four patients developed mucositis, and one of them also developed nonfatal hepatic veno-occlusive disease (VOD). No patients receiving 40 mg/m2 BU developed neurotoxicity (eg, seizures) or interstitial pneumonitis. Prompt and sustained engraftment was observed in the allogeneic BMT recipients, and late graft failure was not seen. The mean BU AUCs were 1,105 mumol/L.min (range, 790 to 2,080) after the first dose and 1,022 mumol/L.min (range, 632 to 1,860) after the 13th dose of BU, comparable to the AUCs in adults given 16 mg/kg of BU. These studies suggest that, in young children, BSA-based dosing of BU (40 mg/m2) provides drug exposures (AUCs) closer to adult values with acceptable toxicities and may improve therapeutic effects. 相似文献
68.
The effects of granulocyte-macrophage colony-stimulating factor (GM- CSF) are not confined to cells of the myeloid lineage. GM-CSF has been shown to have effects on mature T cells and both mature and immature T- cell lines. We therefore examined the GM-CSF responsiveness of murine thymocytes to investigate whether GM-CSF also affected normal immature T lymphocytes. The studies presented here indicate that GM-CSF augments accessory cell (AC)-dependent T-cell receptor (TCR)-mediated proliferation of unseparated thymocyte populations. To identify the GM- CSF responsive cell type, thymic AC and T cells were examined for GM- CSF responsiveness. We found that GM-CSF augmentation of TCR-induced thymocyte proliferation appears to be mediated via augmentation of AC function, and not via direct effects on mature single-positive (SP) thymocytes. Enriched double-negative (DN) thymocytes were also tested for GM-CSF responsiveness. GM-CSF induced the proliferation of adult and fetal DN thymocytes in an AC-independent and TCR-independent single- cell assay. Thus, in contrast to the SP thymocytes, a DN thymocyte population was directly responsive to GM-CSF. GM-CSF therefore may play a direct role in the expansion of DN thymocytes and an indirect role in the expansion of SP thymocytes. 相似文献
69.